News Releases

Filter News Releases by year:
2020 | 2019 | 2018 | 2017 | 2016
Showing results filtered by:
CLEAR ALL
VRC (Vaccine Research Center)
21 Results

January 2020

Volunteer received experimental monoclonal antibody against malaria

First Human Trial of Monoclonal Antibody to Prevent Malaria Opens

January 27, 2020

A Phase 1 clinical trial testing the safety and effectiveness of a monoclonal antibody (mAb) against malaria has begun enrolling healthy adult volunteers at the National Institutes of Health Clinical Center in Bethesda, Maryland. The trial, sponsored by NIH’s National Institute of Allergy and Infectious Diseases (NIAID), is the first to test mAb CIS43LS in humans. It aims to enroll up to 73 volunteers aged 18 through 50 years old who have never had malaria.

Images of animal lungs showing substantial areas of TB infection (top row) or very little or no infection (bottom row)

Changed Route of Immunization Dramatically Improves Efficacy of TB Vaccine

January 01, 2020

Tuberculosis (TB), an ancient disease, is the leading infectious cause of death globally, yet the world’s only licensed TB vaccine, Bacille Calmette-Guerin (BCG), was developed a century ago. Given to infants via a needle placed just under the skin, BCG protects babies from a form of the disease called disseminated TB but is far less effective at preventing pulmonary TB, the major cause of illness and deaths, in teens or adults. 

December 2019

vial of investigational DNA Zika vaccine

NIH-Developed Zika Vaccine Improves Fetal Outcomes in Animal Model

December 19, 2019

An experimental Zika vaccine lowered levels of virus in pregnant monkeys and improved fetal outcomes in a rhesus macaque model of congenital Zika virus infection, according to a new study in Science Translational Medicine. The research was conducted by scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and their collaborators from the University of California, Davis; Duke University; and the University of California, Los Angeles.

August 2019

Colorized scanning electron micrograph of human respiratory syncytial virus (RSV) virions (blue) and labeled with anti-RSV F protein/gold antibodies (yellow) shedding from the surface of human lung epithelial cells.

Experimental Respiratory Syncytial Virus Vaccine Prompts Antibody Surge

August 01, 2019

A novel experimental vaccine against respiratory syncytial virus (RSV), a leading cause of severe respiratory illness in the very young and the old, has shown early promise in a Phase 1 clinical trial. The candidate, DS-Cav1, was engineered and developed by researchers at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, who were guided by their atomic-level understanding of the shape of an RSV protein.

April 2019

volunteer receives an experimental universal influenza vaccine

NIH Begins First-in-Human Trial of a Universal Influenza Vaccine Candidate

April 03, 2019

The first clinical trial of an innovative universal influenza vaccine candidate is examining the vaccine’s safety and tolerability as well as its ability to induce an immune response in healthy volunteers. Scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, developed the experimental vaccine, known as H1ssF_3928. 

January 2019

A healthy volunteer receives an intravenous infusion of mAb114—an experimental treatment for Ebola virus disease

Investigational Monoclonal Antibody to Treat Ebola Is Safe in Adults

January 24, 2019

The investigational Ebola treatment mAb114 is safe, well-tolerated, and easy to administer, according to findings from an early-stage clinical trial published in The Lancet. Eighteen healthy adults received the monoclonal antibody as part of a Phase 1 clinical trial that began in May 2018 at the National Institutes of Health (NIH) Clinical Center in Bethesda, Maryland. The National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center (VRC), part of NIH, developed the investigational treatment and conducted and sponsored the clinical trial.

June 2018

Protein structure diagram illustrates the location of the fusion peptide epitope on the HIV spike, which projects out of the viral membrane. The diagram also shows how a broadly neutralizing antibody binds to the fusion peptide.

HIV Vaccine Elicits Antibodies in Animals that Neutralize Dozens of HIV Strains

June 04, 2018

An experimental vaccine regimen based on the structure of a vulnerable site on HIV elicited antibodies in mice, guinea pigs and monkeys that neutralize dozens of HIV strains from around the world. The findings were reported today in the journal Nature Medicine by researchers at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and their colleagues. 

March 2018

NIH Scientists Say Advanced Vaccines Could Limit Future Outbreaks

March 22, 2018

Novel vaccine technologies are critical to improving the public health response to infectious disease threats that continually emerge and re-emerge, according to scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. In a perspective in The Journal of the American Medical Association, the experts highlight innovations that could significantly shorten the typical decades-long vaccine development timeline.

Malaria sporozoites, the infectious form of the malaria parasite.

Newly Described Human Antibody Prevents Malaria in Mice

March 19, 2018

Scientists have discovered a human antibody that protected mice from infection with the deadliest malaria parasite, Plasmodium falciparum. The research findings provide the basis for future testing in humans to determine if the antibody can provide short-term protection against malaria, and also may aid in vaccine design. Investigators at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, led the research with colleagues at the Fred Hutchinson Cancer Research Center in Seattle.

December 2017

A Zika virus researcher pipets samples at the NIAID Vaccine Research Center lab.

Gene-Based Zika Vaccine is Safe and Immunogenic in Healthy Adults

December 04, 2017

Results from two Phase 1 clinical trials show an experimental Zika vaccine developed by government scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is safe and induces an immune response in healthy adults. The findings will be published on Dec. 4 in The Lancet. NIAID is currently leading an international effort to evaluate the investigational vaccine in a Phase 2/2b safety and efficacy trial.

NIH Statement on World AIDS Day 2017

December 01, 2017

Anthony S. Fauci, M.D., Director, National Institute of Allergy and Infectious Diseases
Maureen M. Goodenow, Ph.D., Director, Office of AIDS Research

September 2017

Diagram of the “three-in-one” HIV antibody. Each segment binds to a different critical site on the virus. 

Three-in-One Antibody Protects Monkeys from HIV-Like Virus

September 20, 2017

A three-pronged antibody made in the laboratory protected monkeys from infection with two strains of SHIV, a monkey form of HIV, better than individual natural antibodies from which the engineered antibody is derived, researchers report in Science today.

March 2017

Phase 2 Zika Vaccine Trial Begins in U.S., Central and South America

March 31, 2017

Vaccinations have begun in a multi-site Phase 2/2b clinical trial testing an experimental DNA vaccine designed to protect against disease caused by Zika infection. The vaccine was developed by government scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).

Protein-structure model shows how the broadly neutralizing antibodies 10-1074 and 3BNC117 each bind to a different site on the SHIV spike, helping prevent the virus from escaping the antibodies.

Monkeys Suppress HIV-Like Virus for Extended Period after Dual-Antibody Treatment

March 13, 2017

Giving monkeys two powerful anti-HIV antibodies immediately after infection with an HIV-like virus enabled the immune systems of some of the animals to control the virus long after the antibodies were gone, scientists at the National Institutes of Health and The Rockefeller University have found.  

Investigational Vaccine Protects Cattle from Respiratory Syncytial Virus

March 10, 2017

A novel vaccine developed by scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, protected cattle from respiratory syncytial virus (RSV) infection, according to research published online in npj Vaccines on March 8. The research was conducted by a team of experts at NIAID, the Pirbright Institute based in the United Kingdom, and the Institute for Research in Biomedicine in Switzerland.

September 2016

Experimental Zika Virus DNA Vaccines Protective in Monkeys

September 22, 2016

Two experimental Zika virus DNA vaccines developed by National Institutes of Health (NIH) scientists protected monkeys against Zika infection after two doses, according to a study published in Science. One of those vaccines is being evaluated in a Phase 1 human trial now under way in three U.S. locations to evaluate the vaccine’s safety and ability to generate immune responses in people.

August 2016

Volunteer receives the NIAID Zika investigational vaccine

NIH Begins Testing Investigational Zika Vaccine in Humans

August 03, 2016

​The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched a clinical trial of a vaccine candidate intended to prevent Zika virus infection. The early-stage study will evaluate the experimental vaccine’s safety and ability to generate an immune system response in participants.

July 2016

image of one of the new signature antibodies

Vaccine Strategy Induces Antibodies that Can Target Multiple Influenza Viruses

July 22, 2016

WHAT:
Scientists have identified three types of vaccine-induced antibodies that can neutralize diverse strains of influenza virus that infect humans. The discovery will help guide development of a universal influenza vaccine, according to investigators at the National Institute of Allergy and Infectious Diseases (NIAID), and the National Human Genome Research Institute (NHGRI), both part of the National Institutes of Health (NIH), and collaborators who conducted the research. The findings appear in the July 21st online edition of Cell.

May 2016

Model of the VRC34.01 antibody

NIH-Led Team Discovers New HIV Vaccine Target

May 12, 2016

A team led by scientists at the National Institutes of Health (NIH) has reported a research trifecta. They discovered a new vulnerable site on HIV for a vaccine to target, a broadly neutralizing antibody that binds to that target site, and how the antibody stops the virus from infecting a cell.

Investigational Malaria Vaccine Protects Healthy U.S. Adults for More than One Year

May 09, 2016

An experimental malaria vaccine protected a small number of healthy, malaria-naïve adults in the United States from infection for more than one year after immunization, according to results from a Phase 1 trial described in the May 9th issue of Nature Medicine.

February 2016

The Ebola virus surface glycoprotein (blue) is shown bound by protective antibodies mAb114 (pink/white) and mAb100 (purple/white).

Experimental Ebola Antibody Protects Monkeys

February 25, 2016

Scientists at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and colleagues have discovered that a single monoclonal antibody—a protein that attacks viruses—isolated from a human Ebola virus disease survivor protected non-human primates when given as late as five days after lethal Ebola infection.